Laahn Ho Foster

ByLarry Anderson, MD, PhD,Caitlin Costello, MD,Laahn Foster, MD Explore the evolving treatment strategies for high-risk smoldering multiple myeloma, emphasizing early intervention and recent clinical advancements. ByLarry Anderson, MD, PhD,Caitlin Costello, MD,Laahn Foster, MD Explore the evolving landscape of high-risk smoldering myeloma treatment options and the challenges in patient management and risk assessment.

Dr. Ian Flinn and Dr. Danielle Brander discuss how advances in targeted therapy have reshaped frontline management and reduced reliance on chemotherapy. The conversation begins with the importance of biomarker testing in CLL. Dr. Brander emphasizes that despite improved therapies, baseline risk stratification remains critical due to disease heterogeneity.

The final section integrates the full COPERNICUS strategy, focusing on proactive toxicity prevention and real world applicability. Dr Santos details the structured prophylactic regimens designed to minimize common adverse events associated with amivantamab and lazertinib. Administration reaction prophylaxis includes dexamethasone based on SKIPPirr data, while venous thromboembolism prevention is addressed through prophylactic anticoagulation.